Concern raised over stroke risk with aromatase inhibitorsManitoba registry turns up findings not seen in trials Unnecessary tests driving thyroid cancer epidemicDiagnosis rates vary widely but mortality remains constant Hormone therapy for breast cancer: When is five years enough? Ten-year treatment adds little benefit in early disease Prostate cancer treatment takes its toll Avoid over-treating and watch for complications, researcher says Chemo-trastuzumab tops in HER2-positive breast cancer Survival results are some of the best ever seen, researcher says Excitement grows over gene therapy for cancer Reprogrammed cells fight leukemia and lymphoma Telemedicine takes cancer care closer to home Radiation oncology program bridges gap between northern cities Kadcyla for metastatic breast cancer First antibody–drug conjugate targeted therapy to be marketed in Canada. New option for pancreatic cancer Is sparing lymph nodes risky in node-positive breast cancer? U.S. study questions sentinel biopsy, but Canadian oncologist says the trend remains toward less extensive surgery First Previous 37 38 39 40 41 Next Last
